Breaking News

Cambrex Breaks Ground on $30M Milan R&D Facility

New facility will expand analytical development and process R&D capabilities.

Cambrex, a global contract development and manufacturing organization (CDMO), has started construction on a new research and development (R&D) facility at its Milan, Italy site.

This $30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants, reinforcing Cambrex’s commitment to supporting the pharmaceutical industry’s most complex small molecule development.

Claudio Russolo, Chief Operating Officer at Cambrex, said, “Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in new technologies and capabilities, but in the future of our people and our partners.”

The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future growth and rising demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, ensuring the capacity to expand and innovate for years to come.

More Cambrex News

In the United States, Cambrex recently completed the initial engineering studies for its new, large-scale API manufacturing plant in Charles City, Iowa. Groundbreaking for the new facility is scheduled to take place in late 2026.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics